CN100591355C - 治疗过度增殖疾病的组合物及其制药用途 - Google Patents

治疗过度增殖疾病的组合物及其制药用途 Download PDF

Info

Publication number
CN100591355C
CN100591355C CN03803734A CN03803734A CN100591355C CN 100591355 C CN100591355 C CN 100591355C CN 03803734 A CN03803734 A CN 03803734A CN 03803734 A CN03803734 A CN 03803734A CN 100591355 C CN100591355 C CN 100591355C
Authority
CN
China
Prior art keywords
phenyl
benzyloxy
pyrrolo
pyrimidin
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN03803734A
Other languages
English (en)
Chinese (zh)
Other versions
CN1630534A (zh
Inventor
C·D·斯泰尔斯
C·加西亚-埃切维里亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CN1630534A publication Critical patent/CN1630534A/zh
Application granted granted Critical
Publication of CN100591355C publication Critical patent/CN100591355C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN03803734A 2002-02-14 2003-02-14 治疗过度增殖疾病的组合物及其制药用途 Expired - Fee Related CN100591355C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35691202P 2002-02-14 2002-02-14
US60/356,912 2002-02-14

Publications (2)

Publication Number Publication Date
CN1630534A CN1630534A (zh) 2005-06-22
CN100591355C true CN100591355C (zh) 2010-02-24

Family

ID=27734705

Family Applications (1)

Application Number Title Priority Date Filing Date
CN03803734A Expired - Fee Related CN100591355C (zh) 2002-02-14 2003-02-14 治疗过度增殖疾病的组合物及其制药用途

Country Status (11)

Country Link
EP (1) EP1476192B1 (https=)
JP (1) JP5053503B2 (https=)
CN (1) CN100591355C (https=)
AT (1) ATE360442T1 (https=)
AU (1) AU2003205768A1 (https=)
BR (1) BR0307629A (https=)
CA (1) CA2476000A1 (https=)
DE (1) DE60313434T2 (https=)
ES (1) ES2283744T3 (https=)
PT (1) PT1476192E (https=)
WO (1) WO2003068265A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
ATE514434T1 (de) * 2004-02-25 2011-07-15 Dana Farber Cancer Inst Inc Hemmer des insulinartigen wachstumsfaktor- rezeptors-1 zur hemmung von tumorzellwachstum
TWI378934B (en) 2004-04-02 2012-12-11 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
US7329495B2 (en) 2004-06-09 2008-02-12 Board Of Regents, The University Of Texas System Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
AU2006292278B2 (en) 2005-09-20 2012-03-08 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
US20110171124A1 (en) 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
CA2783656A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2783665A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2544672A1 (en) 2010-03-09 2013-01-16 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP6255038B2 (ja) 2013-02-26 2017-12-27 トリアクト セラピューティクス，インク． 癌治療
US9381246B2 (en) 2013-09-09 2016-07-05 Triact Therapeutics, Inc. Cancer therapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1040926A (zh) * 1987-11-06 1990-04-04 翁科根公司 细胞生长抑制因子
CN1071586A (zh) * 1991-09-05 1993-05-05 马普科技促进协会 作药物用的突变生长因子受体及其治疗癌的应用
CN1128496A (zh) * 1994-01-07 1996-08-07 休正公司 对与血小板源生长因子有关的疾病如癌症的治疗
CN1237582A (zh) * 1998-05-29 1999-12-08 杭州赛狮生物技术开发有限公司 类胰岛素生长因子受体基因的反义核酸的抑癌作用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1040926A (zh) * 1987-11-06 1990-04-04 翁科根公司 细胞生长抑制因子
CN1071586A (zh) * 1991-09-05 1993-05-05 马普科技促进协会 作药物用的突变生长因子受体及其治疗癌的应用
CN1128496A (zh) * 1994-01-07 1996-08-07 休正公司 对与血小板源生长因子有关的疾病如癌症的治疗
CN1237582A (zh) * 1998-05-29 1999-12-08 杭州赛狮生物技术开发有限公司 类胰岛素生长因子受体基因的反义核酸的抑癌作用

Also Published As

Publication number Publication date
DE60313434T2 (de) 2008-01-10
CA2476000A1 (en) 2003-08-21
PT1476192E (pt) 2007-07-26
DE60313434D1 (de) 2007-06-06
JP2005517040A (ja) 2005-06-09
ES2283744T3 (es) 2007-11-01
WO2003068265A1 (en) 2003-08-21
CN1630534A (zh) 2005-06-22
JP5053503B2 (ja) 2012-10-17
ATE360442T1 (de) 2007-05-15
EP1476192B1 (en) 2007-04-25
BR0307629A (pt) 2005-01-11
AU2003205768A1 (en) 2003-09-04
EP1476192A1 (en) 2004-11-17

Similar Documents

Publication Publication Date Title
CN100591355C (zh) 治疗过度增殖疾病的组合物及其制药用途
TWI556820B (zh) Ｈｓｐ９０抑制劑之組合
CA2303577C (en) Qt dispersion and heart rate variability improvement with crf antagonists to prevent sudden death
US8119649B2 (en) Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia
JPH09132528A (ja) コルチコトロピン放出因子アンタゴニストの新規使用
JP2013151530A (ja) Ｂｃｒ−ａｂｌ／ｃ−ｋｉｔ／ｐｄｇｆ−ｒｔｋ阻害剤を含む、がんの処置用の組合せ剤
JP2014503566A5 (https=)
BR112021006033A2 (pt) Uso de um inibidor de um transportador da família ent no tratamento de câncer e combinação do mesmo com um antagonista do receptor de adenosina
JP2013127001A (ja) ピリミジルアミノベンズアミド化合物であるタンパク質キナーゼ阻害剤および１７−ａａｇのようなｈｓｐ９０阻害剤を含む組合せ剤
EP1385522B1 (en) Combination comprising a signal transduction inhibitor and an epothilone derivative
US20050215564A1 (en) Methods and compositions for treating hyperproliferative conditions
AU2002308218A1 (en) Combination comprising a signal transduction inhibitor and an epothilone derivative
JP2009532497A (ja) 癌を処置するための治療剤の組合せ
JP2007513967A (ja) 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物
WO2021089419A1 (en) Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies
MX2007015159A (es) Combinacion de compuestos de pirimidil-amino-benzamida e imatinib para el tratamiento o la prevencion de enfermedades proliferativas.
JP2005526821A (ja) 癌の処置におけるグリベック（ｓｔｉ５７１）とサイクリン依存性キナーゼインヒビター、とりわけフラボピリドールとの組合せ剤
HK40069821B (zh) 治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合
HK40069821A (en) Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies
ZA200306404B (en) Combination comprising a signal transduction inhibitor and an epothilone derivative.
HK1062266B (en) Combination comprising a signal transduction inhibitor and an epothilone derivative

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100224

Termination date: 20140214